cms.bioaccessla.com

Tag: Latin America clinical trials

  • First-in-Human Trial Readiness in Latin America: The Cross-Functional Gate Before Submission

    First-in-Human Trial Readiness in Latin America: The Cross-Functional Gate Before Submission

    A first-in-human (FIH) study in Latin America can move quickly only when the sponsor’s evidence tells one consistent story. The protocol, risk analysis, investigator brochure or device dossier, informed-consent materials, ethics package, and import plan must describe the same intended use, population, procedure, and safeguards. If those documents drift apart, a fast regulatory pathway can turn into a long clarification cycle.

    Internal experience across early-stage programs shows that readiness is less about producing more pages and more about closing the handoffs between regulatory, clinical, quality, site, and supply-chain teams. This practical gate helps MedTech founders and regulatory directors test whether a study is ready for country submissions without relying on a single calendar estimate.

    1. Start with one study story

    Before country tailoring begins, write a concise study narrative that every contributor can use. State what the investigational device is, who will use it, for which patients, in what setting, and what the FIH study is designed to learn. Separate proof-of-principle or early-feasibility questions from claims that will require a later pivotal study or market authorization.

    Then link each major claim to evidence. A risk control in the technical file should appear in the protocol’s monitoring plan and, where relevant, in the training and consent materials. The primary endpoint should match the feasibility objective. The procedure described for the investigator should match the version assessed by the ethics committee. This simple traceability exercise exposes contradictions before an authority or committee has to ask about them.

    • Intended use: define the population, setting, operator, procedure, and boundaries of use.
    • Risk controls: show foreseeable hazards, mitigations, stopping rules, and escalation contacts.
    • Clinical objective: use a focused endpoint set that answers the early-stage question without promising more than the study can demonstrate.
    • Participant protection: connect eligibility, follow-up, adverse-event handling, and consent language to the risk profile.
    • Version control: maintain one controlled source for device specifications, protocol revisions, and country annexes.

    2. Map the regulatory and ethics lanes before filing

    Latin America is not one regulatory pathway. A country matrix should identify the competent authority, ethics route, submission format, required translations, import documentation, responsible local party, and the definition of a complete submission. It should also distinguish a statutory or published review period from a practical activation forecast that includes clarifications, contracts, training, and shipment.

    Brazil illustrates why this distinction matters. Law No. 14.874/2024 establishes a 30-business-day period for an ethics committee to issue its opinion after accepting a complete document set, and a 90-business-day ceiling for the health analysis of primary clinical-trial petitions covered by the law. Those provisions are useful planning inputs, but they do not eliminate sponsor work before acceptance or operational work after authorization. The official English translation of Law No. 14.874/2024 should be checked for scope and the current implementation context.

    Colombia requires a different document conversation. INVIMA’s clinical-investigation materials identify the technical and ethical information needed for medical-device studies and publish current forms for protocol evaluation, ethics-committee assessment, notifications, and periodic reports. The sponsor should confirm the latest checklist rather than reusing a prior country’s format. The INVIMA clinical-investigation page is the appropriate starting point for current requirements.

    3. Treat site and import readiness as submission evidence

    An approved protocol cannot enroll if the site cannot perform the procedure, protect participants, or receive the investigational product. Site feasibility should therefore be documented before submission, not treated as a post-approval procurement task. Confirm investigator experience, procedure volume, equipment, imaging or laboratory support, emergency coverage, data systems, and the site’s ability to meet the visit schedule.

    For an investigational device, also map the physical journey into the country. Identify the importer of record or other responsible local party, customs broker, shipping documents, product description, packaging, storage conditions, and receipt inspection. The receiving site should know who can release a shipment, where it will be stored, how it will be labeled, and how deviations will be documented. If those answers are missing, the regulatory package is operationally incomplete even when the PDF set looks finished.

    Use an owner-and-dependency map for each handoff. Regulatory owns the submission matrix; clinical owns protocol and endpoint consistency; quality owns controlled versions and deviation pathways; the site owns readiness evidence; and logistics owns import and delivery controls. A single accountable person should resolve conflicts rather than allowing parallel teams to submit different answers.

    4. Run a documented readiness gate

    Two weeks before the planned filing, hold a cross-functional gate with the country team and proposed site. The objective is not to read every page aloud. It is to test the few dependencies that can stop the study.

    • Traceability check: reconcile intended use, device configuration, endpoints, risks, and consent language across all core documents.
    • Completeness check: confirm forms, translations, signatures, fees, certificates, and local representative details for the target country.
    • Site check: verify staff training, equipment, standard operating procedures, safety escalation, and recruitment assumptions.
    • Import check: test the shipment dossier with the broker and receiving site before the first dispatch.
    • Clarification check: prepare an evidence map showing who will answer likely questions and how quickly.

    Record open items with an owner, due date, and submission impact. If a high-risk item is unresolved, move the filing date rather than hiding the issue inside an optimistic timeline. A short, coherent dossier usually creates more speed than a large dossier assembled in parallel without a common source of truth.

    Frequently asked questions

    What is the most common FIH readiness failure?
    Document inconsistency is a frequent failure: the protocol, device description, risk controls, and consent materials describe different versions of the study. A traceability matrix finds this before submission.

    Can a sponsor use the same dossier in every Latin American country?
    The scientific core can be reused, but country forms, translations, ethics routes, local responsibilities, and import rules require tailored annexes. Reuse controlled content; do not assume identical filing requirements.

    When should import planning begin?
    Begin during site selection and protocol planning. Shipment classification, local responsibility, customs documents, storage, and receipt procedures can affect the activation sequence and should be tested before authorization.

    For sponsors planning an early-stage MedTech study, the practical goal is a submission that regulators, ethics committees, investigators, and logistics partners can all execute from the same study story. That is the readiness gate that turns a promising FIH concept into a controllable Latin America launch plan.

  • Importer of Record (IOR) for Multi‑Country MedTech Trials in Latin America: A Sponsor‑Ready Playbook

    Importer of Record (IOR) for Multi‑Country MedTech Trials in Latin America: A Sponsor‑Ready Playbook

    In Latin America, getting a first-in-human or early-stage MedTech study approved is only half the battle. The other half is operational: getting investigational devices, accessories, and consumables through customs reliably—on time, every time, across multiple countries.

    That is why the Importer of Record (IOR) decision becomes a critical-path item for sponsors. An IOR strategy is not just “paperwork.” It is the control system that determines who is legally responsible for the import, who holds product registrations (when needed), how the shipment is classified, and who can react when a package is held.

    This playbook explains what an IOR does in the context of MedTech clinical trials in Latin America, how to choose an IOR model for multi-country programs, and which checklists reduce the most common causes of delays.

    What is an Importer of Record (IOR) in a clinical trial context?

    An Importer of Record is the entity that assumes legal responsibility for bringing goods into a country. In MedTech clinical trials, the IOR is typically responsible for:

    • Customs declaration and classification (HS codes, declared value, product description consistency)
    • Regulatory alignment for investigational-use shipments (where applicable)
    • Coordination with brokers and resolution of holds, inspections, and documentation requests
    • Chain-of-custody documentation and receiving confirmation for sites
    • Import compliance (licenses, tax IDs, authorizations, and record retention)

    For a sponsor running a multi-country LATAM program, the IOR is a practical risk owner: when the shipment is delayed, the IOR is the party with standing to respond, correct documents, and release the goods.

    Why the IOR decision becomes a critical path in Latin America

    Multi-country execution introduces parallel risk. Even if each country has a clean regulatory path, supply chain variability can create staggered site activations and missed enrollment windows. Common delay drivers include:

    • Inconsistent product descriptions between invoice, packing list, airway bill, and regulatory letters
    • Misaligned declared value (e.g., “free of charge” shipments that trigger valuation questions)
    • Unclear purpose-of-import (commercial vs investigational vs donation terminology)
    • Missing or outdated IOR registrations (tax IDs, legal entity status, import licenses)
    • Cold chain ambiguity (temperature ranges not specified, packaging validation gaps)

    The impact is rarely isolated. A single held shipment can create a cascade: rescheduled site initiation visits, re-booked monitoring travel, delayed training, and protocol deviations when replacement components arrive late.

    IOR models for multi-country LATAM MedTech trials (and how to choose)

    There is no universal best model. The right answer depends on the investigational product profile, the number of countries, and how much operational control the sponsor needs.

    Model A: Site or hospital as IOR

    When it works: small studies, low-complexity devices, and highly experienced research institutions with established import processes.

    Risks: sites often lack bandwidth for repeated customs interactions; import experience varies widely; accountability becomes fragmented across countries.

    Model B: Local distributor as IOR

    When it works: later-stage programs where a commercial partner already exists and can support consistent import flows.

    Risks: distributor incentives may not match trial urgency; conflict may arise around product classification, pricing, or future commercial rights.

    Model C: Sponsor-appointed specialized IOR/clinical logistics partner

    When it works: multi-country studies, time-sensitive shipments, accessory-heavy devices, and programs requiring consistent compliance documentation.

    Benefits: centralized process control, repeatable templates, proactive broker management, and stronger visibility across the supply chain.

    Sponsor selection criteria should include: country coverage, medical product import track record, temperature-controlled capability (if relevant), speed of document turnaround, and documented escalation procedures.

    The sponsor-ready IOR checklist (what to confirm before first shipment)

    • Legal entity readiness: confirm the IOR’s legal registration, tax identifiers, and ability to act as importer for investigational medical products.
    • Defined shipment purpose language: use consistent terms such as “investigational-use medical device for clinical study” and avoid mixed commercial language.
    • Standard document pack: commercial invoice (even if no charge), packing list, airway bill, letter of authorization, and study documentation as required.
    • HS code governance: lock a primary HS classification per SKU/component and document the rationale for re-use across shipments.
    • Broker alignment: confirm who the broker is, how communications flow, and who can approve changes under time pressure.
    • Receiving plan: define site receiving hours, quarantine process (if any), and confirmation steps to close the logistics loop.

    In multi-country programs, treat this checklist as a controlled document. Once validated, it becomes the baseline for every country pack with only country-specific annexes.

    How to reduce customs holds and avoid “silent delays”

    Many delays occur because the sponsor does not hear about an issue until the shipment has already been held for days. Reduce that risk with:

    • Pre-alerts: send document packs to the IOR/broker before shipment departure for pre-review.
    • Single source of truth: maintain a shipment register shared with the IOR and the clinical team (SKU, lot/serial ranges, destination sites, temperature requirements).
    • Escalation SLAs: require response times for holds (e.g., 2–4 hours during business days) and define who can approve revised declarations.
    • Component rationalization: where possible, reduce “mixed shipments” with many line items that increase classification complexity.

    Sponsors should also build a buffer into the activation plan. Even with a strong IOR, variability exists. The objective is not perfection; it is predictable, recoverable execution.

    FAQ

    Do we need one IOR per country for a multi-country LATAM trial?

    Yes—imports occur at the country level, so each country requires an importer. The strategic decision is whether to use the same specialized partner (with local entities) across countries to standardize documentation and escalation.

    Can we ship devices as “no commercial value” to simplify customs?

    Not necessarily. “No commercial value” language can trigger valuation questions. A clearer approach is to declare an appropriate value and describe the purpose consistently as investigational-use for a clinical study.

    What should sponsors measure to manage IOR performance?

    Track time from shipment tender to customs release, number of holds per shipment, root causes of holds, and time-to-response during escalation. These metrics quickly reveal whether the IOR process is improving or drifting.

    Bottom line: In Latin America, the IOR model is a study design decision as much as an operations decision. Define it early, standardize it across countries, and your activation timeline becomes far more reliable.